A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Duliang Soft Capsule in Patients with Chronic Daily Headache

Table 3

Change in accompanying symptoms from baseline to after 4 weeks of treatment in both groups.

Symptoms	DSC group (%)		1 values	Placebo group (%)		2 values
	Pretreatment	Posttreatment		Pretreatment	Posttreatment
Nausea	135 (39.94%)	57 (16.68%)	<0.01	43 (38.74%)	14 (12.61%)	<0.01
Vomiting	60 (17.75%)	27 (7.99%)	<0.01	29 (26.13%)	8 (7.21%)	<0.01
Photophobia	124 (36.69%)	60 (17.15%)	<0.01	35 (31.53%)	23 (20.72%)	0.01
Phonophobia	207 (61.24%)	119 (35.21%)	<0.01	60 (54.05%)	35 (31.53%)	<0.01
Dizziness	197 (58.28%)	126 (37.28%)	<0.01	73 (65.77%)	49 (44.14%)	<0.01